Jushi Holdings (JUSHF) Income towards Parent Company (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Income towards Parent Company of -$7.3 million for Q2 2026, up 40.56% year-over-year from -$5.2 million in Q2 2025, and up 63.07% quarter-over-quarter from -$19.8 million in Q1 2026.
Jushi Holdings (JUSHF) Income towards Parent Company (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Income towards Parent Company for 6 consecutive years, with -$7.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Income towards Parent Company rose 40.56% year-over-year to -$7.3 million; the TTM figure through Jun 2026 stood at -$66.4 million (down 14.86% YoY), while the FY2025 annual figure was -$68.6 million, down 40.62% from the prior year.
- Income towards Parent Company rose to -$7.3 million in Q2 2026 per JUSHF's latest filing, from -$19.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $12.1 million in Q2 2022 and bottomed at -$139.9 million in Q4 2022.
- Historically, Income towards Parent Company has averaged -$22.9 million across 5 years, with a median of -$16.5 million in 2024.
- On a YoY basis, Income towards Parent Company climbed as much as 357.74% in 2022 and fell as far as 2353.05% in 2022.
- Jushi Holdings' Income towards Parent Company stood at -$139.9 million in 2022, then soared by 87.13% to -$18.0 million in 2023, then soared by 30.75% to -$12.5 million in 2024, then declined by 24.77% to -$15.6 million in 2025, then jumped by 52.89% to -$7.3 million in 2026.
- Business Quant data shows JUSHF's Income towards Parent Company at -$7.3 million in Q2 2026, -$19.8 million in Q1 2026, and -$15.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.33 Mn |
| Mar 31, 2026 | -19.85 Mn |
| Dec 31, 2025 | -15.56 Mn |
| Sep 30, 2025 | -23.69 Mn |
| Jun 30, 2025 | -12.33 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -12.47 Mn |
| Sep 30, 2024 | -16.02 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -18.36 Mn |
| Dec 31, 2023 | -18.00 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -14.04 Mn |
| Mar 31, 2023 | -12.44 Mn |
| Dec 31, 2022 | -139.94 Mn |
| Sep 30, 2022 | -54.70 Mn |
| Jun 30, 2022 | 12.07 Mn |
| Mar 31, 2022 | -19.76 Mn |
| Dec 31, 2021 | 6.21 Mn |
| Sep 30, 2021 | 39.68 Mn |